Exelixis (EXEL) Other Non Operating Income (2010 - 2026)
Exelixis (EXEL) posted quarterly Other Non Operating Income of $219000.0 for Q2 2026, up 189.39% year-over-year from $75677.0 in Q2 2025, and up 376.09% quarter-over-quarter from $46000.0 in Q1 2026.
Powered by 
Analysis
Exelixis (EXEL) Other Non Operating Income (2010 - 2026) Analysis & Trends
Exelixis' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $219000.0 for Q2 2026.
- In Q2 2026, Other Non Operating Income rose 189.39% year-over-year to $219000.0; the TTM figure through Apr 2026 stood at $266000.0 (up 192.04% YoY), while the FY2026 annual figure was -$198000.0, down 48.87% from the prior year.
- Other Non Operating Income for Q2 2026 stood at $219000.0, up from $46000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $289000.0 in Q3 2023, with the low at -$337000.0 in Q4 2022.
- The 5-year median for Other Non Operating Income is -$29000.0 (2024), against an average of -$12705.9.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income surged 518.84% in 2023, then plunged 5640.0% in 2024.
- Exelixis' Other Non Operating Income stood at -$337000.0 in 2022, then jumped by 59.35% to -$137000.0 in 2023, then soared by 78.83% to -$29000.0 in 2024, then sank by 68.97% to -$49000.0 in 2025, then surged by 546.94% to $219000.0 in 2026.
- Business Quant data shows EXEL's Other Non Operating Income at $219000.0 in Q2 2026, $46000.0 in Q1 2026, and -$49000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 54,000.00 |
| Apr 3, 2026 | 219,000.00 |
| Jan 2, 2026 | 46,000.00 |
| Oct 3, 2025 | -49,000.00 |
| Jul 4, 2025 | 50,000.00 |
| Apr 4, 2025 | -245,000.00 |
| Jan 3, 2025 | 272,000.00 |
| Sep 27, 2024 | -29,000.00 |
| Jun 28, 2024 | -287,000.00 |
| Mar 29, 2024 | -89,000.00 |
| Dec 29, 2023 | -137,000.00 |
| Sep 29, 2023 | 289,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | -54,000.00 |
| Dec 30, 2022 | -337,000.00 |
| Sep 30, 2022 | -69,000.00 |
| Jul 1, 2022 | 45,000.00 |
| Apr 1, 2022 | 164,000.00 |
| Dec 31, 2021 | -64,000.00 |
| Oct 1, 2021 | -19,000.00 |